Gilead licenses respiratory, herpes antiviral research programs from Novartis
Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.
New Delhi: Gilead Sciences, Inc. has announced recently that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.
Also Read: Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report
Commenting on the same, John McHutchison AO, MD, Gilead's Chief Scientific Officer and Head of Research and Development said, "Today's announcement builds on Gilead's heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options."
Gilead's antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.
Also Read: Gilead Sciences chooses Chengdu Hi-tech Zone for Western China Operation Center project
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd